Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorlatinib in Children With Newly Diagnosed High-Grade Glioma With ROS-1 or ALK Fusion
NCT06333899Phase 1Recruiting
- Sponsor
- Nationwide Children's Hospital
- Start
- Aug 2025
- Primary completion
- Jul 2029
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 6
01
Overview
Phase 1, open-label trial of lorlatinib in glioma (4 arms), sponsored by Nationwide Children's Hospital. Primary endpoints: Disease Control Rate at 8 weeks and Adverse Events. Started Aug 2025; status: recruiting.
02
Drugs
lorlatinib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT06333899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06333899.